前列腺癌
获批药物
靶向骨微环境
- Bisphosphonates
- Zoledronic acid
- Risedronate
- Alendronic Acid
- Clodronate disodium tetrahydrate
- RANKL
- Denosumab
- Calcium Channels [2]
- Thapsigargin
- GSK1016790A
- Suramin sodium salt
- ML-9 HCl
- SKF96365
- CarboxyaMidotriazole orotate
- Diethylstilbestrol
- 5-BDBD
抗血管生成 [3]
靶向PI3K/AKT/mTOR [1]
- PI3K/mTOR
- Apitolisib
靶向表观遗传标志物 [1]
- p300/CBP
- Inobrodib
- BET bromodomain
- Birabresib
- Mivebresib
- Molibresib
- ZEN-3694
- DNMT
- Azacitidine
- Decitabine
靶向WNT通路 [1]
- WNT-5A
- Foxy-5
- VEGF-A
- Bevacizumab
- ETAR
- Zibotentan
- FGFR
- Erdafitinib
- Masitinib
- VEGFR
- Sunitinib
- Cabozantinib
- TGFβR1
- Galunisertib
- Anti-TGFb1
- SRC
- Dasatinib
- Saracatinib
- MEK
- Trametinib
